On November 3, 2022 Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, reported that it will present updated interim data from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma (RRMM) in a poster presentation at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition being held in person in New Orleans, Louisiana and virtually from December 10-13, 2022 (Press release, Harpoon Therapeutics, NOV 3, 2022, View Source [SID1234623133]). HPN217 targets B-cell maturation antigen (BCMA) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC) platform designed to recruit a patient’s own immune cells to kill tumor cells.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The updated interim results from the Phase 1 trial establish clinical proof of concept of HPN217 in heavily pretreated relapsed/refractory multiple myeloma and provide further clinical validation of our proprietary TriTAC T cell engager platform," said Julie Eastland, President and Chief Executive Officer of Harpoon Therapeutics. "At ASH (Free ASH Whitepaper) 2022, we look forward to presenting updated clinical results from the ongoing HPN217 trial in patients with RRMM, including additional safety, efficacy and pharmacodynamic data from patients enrolled at higher dose levels."
Details of the ASH (Free ASH Whitepaper) poster presentation are as follows:
Abstract Title: Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
Publication Number: 3240
Session Number/Title: Session 653 – Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II
Session Date, Time: Sunday, December 11 from 6:00 – 8:00 p.m. CT
Location: Ernest N. Morial Convention Center, Hall D
The poster will also be available on Harpoon’s website following the presentation.
For more details about the ASH (Free ASH Whitepaper) Annual Meeting, please visit: View Source
In November 2019, Harpoon Therapeutics and AbbVie announced a licensing agreement and option to advance HPN217 and expand an existing discovery collaboration. Under the terms of the agreement, AbbVie may exercise its option to license HPN217 after completion of the Phase 1/2 clinical trial.